STAT3 and lung carcinoma: Overexpression of STAT3 in Non-Small Cell Lung Cancer (NSCLC) patients is a strong predictor of poor prognosis, cationic solid lipid nanoparticles (cSLN) were used to deliver RNAi-mediating plasmid DNA targeting STAT3 in cisplatin resistant lung cancer cells (182, 183).